Invesco
BCAX

Invesco’s Bicara Therapeutics BCAX Stock Holding History

Invesco’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$630K Buy
31,650
+10,644
+51% +$183K ﹤0.01% 3063
2025
Q4 		$354K Buy
21,006
+3,595
+21% +$61.4K ﹤0.01% 3327
2025
Q3 		$275K Buy
17,411
+534
+3% +$5.98K ﹤0.01% 3451
2025
Q2 		$157K Buy
16,877
+1,962
+13% +$23.4K ﹤0.01% 3574
2025
Q1 		$194K Sell
14,915
-409
-3% -$5.43K ﹤0.01% 3518
2024
Q4 		$267K Buy
+15,324
New +$319K ﹤0.01% 3451

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Invesco's BCAX Position: Q1 2026 in Review

Invesco increased its Bicara Therapeutics (BCAX) stake by 51% in Q1 2026, buying an estimated $183K and bringing the position to 31,650 shares worth $630K. The position accounts for ﹤0.01% of the portfolio, ranked #3063.

Invesco first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Invesco held 31,650 shares of Bicara Therapeutics worth $630K as of Q1 2026.
  • Invesco bought 10,644 Bicara Therapeutics shares in Q1 2026, an estimated $183K.
  • Bicara Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3063 holding.
  • Invesco first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.